Vertex Pharmaceuticals Incorporated (VX1.DE)

XETRA - XETRA Delayed Price. Currency in EUR

438.60

+2.80

(+0.64%)

At close: 05:35PM CET

News

Simply Wall St.
Vertex Pharmaceuticals (NASDAQ:VRTX) shareholders are still up 137% over 3 years despite pulling back 3.4% in the past week
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But in contrast you can...
Motley Fool
Down 47% Since March, Is CRISPR Therapeutics Stock a Buy on the Dip?
On Nov. 21, shares of CRISPR Therapeutics (NASDAQ: CRSP) were down 47% from a peak they reached in March. After all, it's been less than a year since regulators in the U.S. and E.U. approved its first therapy, Casgevy, to treat two blood-based disorders. Casgevy's initial launch hasn't been as exciting as investors and its partner, Vertex Pharmaceuticals (NASDAQ: VRTX), had hoped.